Maria Felicia Faienza1, Giacomina Brunetti2, Lorenzo Sanesi3, Graziana Colaianni3, Monica Celi4, Laura Piacente1, Gabriele D'Amato5, Ernestina Schipani6, Silvia Colucci2, Maria Grano7. 1. Department of Biomedical Science and Human Oncology, Paediatric Unit, University of Bari, Bari, Italy. 2. Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Human Anatomy and Histology, School of Medicine-University of Bari, Italy. 3. Department of Emergency and Organ Transplantation, School of Medicine-University of Bari, Italy. 4. Department of Orthopedics and Traumatology, Tor Vergata University of Rome, Italy. 5. Neonatal Intensive Care Unit, Di Venere Hospital, Bari, Italy. 6. Departments of Medicine and Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA. 7. Department of Emergency and Organ Transplantation, School of Medicine-University of Bari, Italy. Electronic address: maria.grano@uniba.it.
Abstract
AIM: Irisin is a new peptide produced mainly by the skeletal muscle playing an important role both in glucose/energy homeostasis and bone metabolism. Childhood type 1 diabetes mellitus (T1DM) is associated with decreased bone mass. We aimed to evaluate irisin levels in TD1M children and their correlation with bone metabolism and glycaemic control. METHODS: Ninety-six T1DM subjects (12.2 ± 4 years), 56 on multiple daily injections (MDI), 40 on continuous subcutaneous insulin infusion (CSII), and 34 controls were included in the study. Irisin and bone remodeling markers were quantified in sera from patients and controls. Bone mineral density (BMD) was evaluated by QUS. RESULTS: Increased irisin levels were found in T1DM patients respect to controls (p < 0.001). With adjustment for age, irisin levels significantly correlated negatively with HbA1c% (r = -0.105, p < 0.001), years of diabetes (r = -0.07, p < 0.04), 25(OH)-Vitamin D (r = -0.175, p < 0.0001), and positively with BTT-Z-score (r = 0.088, p = 0.016), and osteocalcin (r = 0.059, p < 0.04). We detected the highest levels of irisin in CSII patients compared to MDI and controls (p < 0.001 and p < 0.007 respectively). CONCLUSIONS: We demonstrated high irisin levels in T1DM children and the association of highest irisin amounts to a better glycaemic control and bone health in TDM1 subjects on CSII.
AIM: Irisin is a new peptide produced mainly by the skeletal muscle playing an important role both in glucose/energy homeostasis and bone metabolism. Childhood type 1 diabetes mellitus (T1DM) is associated with decreased bone mass. We aimed to evaluate irisin levels in TD1M children and their correlation with bone metabolism and glycaemic control. METHODS: Ninety-six T1DM subjects (12.2 ± 4 years), 56 on multiple daily injections (MDI), 40 on continuous subcutaneous insulin infusion (CSII), and 34 controls were included in the study. Irisin and bone remodeling markers were quantified in sera from patients and controls. Bone mineral density (BMD) was evaluated by QUS. RESULTS: Increased irisin levels were found in T1DM patients respect to controls (p < 0.001). With adjustment for age, irisin levels significantly correlated negatively with HbA1c% (r = -0.105, p < 0.001), years of diabetes (r = -0.07, p < 0.04), 25(OH)-Vitamin D (r = -0.175, p < 0.0001), and positively with BTT-Z-score (r = 0.088, p = 0.016), and osteocalcin (r = 0.059, p < 0.04). We detected the highest levels of irisin in CSII patients compared to MDI and controls (p < 0.001 and p < 0.007 respectively). CONCLUSIONS: We demonstrated high irisin levels in T1DM children and the association of highest irisin amounts to a better glycaemic control and bone health in TDM1 subjects on CSII.
Authors: S E Beray; M E Atabek; Y Kücükkagnici; S Kurban; M B Selver; M S Iyisoy Journal: Acta Endocrinol (Buchar) Date: 2022 Jan-Mar Impact factor: 1.104
Authors: Aleksandra Żebrowska; Marcin Sikora; Anna Konarska; Anna Zwierzchowska; Tomasz Kamiński; Anna Robins; Barbara Hall Journal: Ther Adv Endocrinol Metab Date: 2020-05-27 Impact factor: 3.565
Authors: Ilse Yessabel Martinez Munoz; Eneida Del Socorro Camarillo Romero; Jose de Jesus Garduno Garcia Journal: Int J Endocrinol Date: 2018-10-09 Impact factor: 3.257
Authors: Maria Felicia Faienza; Giuseppe Lassandro; Mariangela Chiarito; Federica Valente; Loredana Ciaccia; Paola Giordano Journal: Int J Environ Res Public Health Date: 2020-03-13 Impact factor: 3.390